Table 2 Clinical and laboratory features of HLA-B52-positive patients with LVV
Variable | TAK, n = 10 | LVV with GCA features, n = 10 | p value |
|---|---|---|---|
Age at onset, years, mean ± SD | 29.2 ± 11.9 | 70.1 ± 9.1 | < 0.001 |
Female, n (%) | 7/10 (70.0) | 5/10 (50.0) | 0.65 |
Positive temporal artery findings, n (%) | 0/10 (0) | 4/10 (40.0) | 0.09 |
PMR diagnosed, n (%) | 0/10 (0) | 8/10 (80.0) | < 0.001 |
Jaw claudication, n (%) | 0/9 (0) | 1/9 (11.1) | 1 |
Biologics usage, n (%) | 8/10 (80) | 4/9 (44.4) | 0.17 |
History of relapse, n (%) | 7/10 (70) | 3/9 (33.3) | 0.18 |
Newly diagnosed and untreated patients, n | 5/10 | 10/10 | Â |
Laboratory findings | |||
 aPL, n (%) | 0/4 (0) | 4/6 (66.7) | 0.08 |
 HLA-B52, n (%) | 10/10 (100) | 10/10 (100) |  |
 HLA-DR4, n (%) | 0/9 (0) | 4/9 (44.4) | 0.08 |
 CRP, mg/dl | 4.9 (1.8–12.9) | 7.5 (4.3–10.8) | 0.50 |
 Platelet count, × 104 cells/μl | 47.1 (36.8–53.1) | 44.1 (35.0–49.5) | 0.67 |